Standout Papers

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have av... 2003 2026 2010 2018 2.6k
  1. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial (2003)
    Peter Sever, Björn Dahlöf et al. The Lancet
  2. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial (2005)
    Björn Dahlöf, Peter Sever et al. The Lancet
  3. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension (2010)
    Peter M. Rothwell, Sally C. Howard et al. The Lancet
  4. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial (2015)
    Bryan Williams, Thomas M. MacDonald et al. The Lancet
  5. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary (2004)
    Bryan Williams, Neil R Poulter et al. BMJ
  6. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk (2019)
    Michelle L. O’Donoghue, Sergio Fazio et al. Circulation
  7. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease (2017)
    Marc P. Bonaca, Patrice Nault et al. Circulation
  8. Effects of β blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke (2010)
    Peter M. Rothwell, Sally C. Howard et al. The Lancet Neurology
  9. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials (2015)
    Jessica L. Mega, Nathan O. Stitziel et al. The Lancet

Immediate Impact

2 by Nobel laureates 1 from Science/Nature 134 standout
Sub-graph 1 of 11

Citing Papers

Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a)
2025 Standout
Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension
2023 Standout
2 intermediate papers

Works of Peter Sever being referenced

Effects of β blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke
2010 Standout
Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension
2010 Standout
and 1 more

Author Peers

Author Last Decade Papers Cites
Peter Sever 9523 6768 4975 189 16.2k
Mark J. Caulfield 8024 5847 6042 169 16.6k
Gordon T. McInnes 8395 4240 5206 123 13.0k
Eoin OʼBrien 15435 6880 3990 261 20.7k
Jan Östergren 13547 4526 5350 135 18.7k
Prakash Deedwania 11089 5493 5703 379 18.7k
Ole Færgeman 5016 9714 5527 191 16.0k
Barry R. Davis 13012 9207 5799 253 25.0k
Gareth Beevers 7507 3679 4330 59 12.0k
James M. McKenney 4894 10019 7409 154 20.7k
Stuart M. Cobbe 6389 8907 4608 158 17.7k

All Works

Loading papers...

Rankless by CCL
2026